What is the Share Price of Concord Drugs Ltd?

Concord Drugs Ltd share price is ₹30.13 As on 09 May, 2025|09:17

Home
>
Stocks
>
Concord Drugs Ltd

Concord Drugs Ltd Share Price

Q: What is the Market Cap of Concord Drugs Ltd?

The Market Cap of Concord Drugs Ltd is ₹30.1 As on 09 May, 2025|09:17

Q: What is PE Ratio of Concord Drugs Ltd?

The P/E ratio of Concord Drugs Ltd is 0 As on 09 May, 2025|09:17

Q: What is PB Ratio of Concord Drugs Ltd?

The PB ratio of Concord Drugs Ltd is 0.89 As on 09 May, 2025|09:17

₹ 0.00 0 (0%)
Updated on 01-01-1970 5:30 AM

Stock Rating

BSE

Pros 0

Cons 7

Concord Drugs Ltd Price Performance

Day's Low
₹0

Day's High
₹0

₹ 0

52-w low
₹0

52-w high
₹0

Day's open
₹0
Previous close
₹0
VWAP
₹0
Lower price band
₹0
Upper price band
₹0

Today's Market Action

Its last traded stock price on BSE was 30.13 down by -2.99%. The total volume of shares on NSE and BSE combined was 1,539 shares. Its total combined turnover was Rs 0.00 crores.

Concord Drugs Ltd Medium and Long Term Market Action

The stock price of Concord Drugs Ltd is down by -100% over the last one month. Don't forget to check the full stock price history in the table below.

Concord Drugs Ltd Fundamentals

Market Cap (Cr): 30.1
Book Value (₹):
Stock P/E:
Revenue (Cr):
Total Debt (Cr):

Face Value (₹):
Roce (%):
ROE (%):
Earnings (Cr):
Promoter’s Holdings (%):

EPS (₹):
Debt to Equity:
Dividend Yield (%):
Cash (Cr):

Concord Drugs Ltd Mutual fund holdings and trends

FUND NAME	Quantity	Monthly Change (Qty)

Concord Drugs Ltd Shareholding Pattern

Similar Stocks

Company	Price	Market Cap (Cr)	P/E

About Concord Drugs Ltd

Data not available.

Concord Drugs Ltd FAQ's

What is Share Price of Concord Drugs Ltd?

What is the Market Cap of Concord Drugs Ltd?

What is PE Ratio of Concord Drugs Ltd?

What is PB Ratio of Concord Drugs Ltd?

What is the CAGR of Concord Drugs Ltd?

How to Buy Concord Drugs Ltd Share?

Can I buy Concord Drugs Ltd from Samco?

How do I buy Concord Drugs Ltd from Samco?

Financials

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

News

Review

Pros

No Data Available

Cons

Low Sustainable RoE
The company's sustainable return on equity is lower than the expected cost of capital which implies that the underlying business will destruct value over a period of time due to it's inability to generate superior returns on capital.
Low Return on Capital Employed
The company is unable to generate sufficient return on capital employed which impairs it's ability to generate high return for shareholders after accounting for taxes, interest and other non-equity stakeholders.
Low Interest Coverage
The company has a very low Interest coverage ratio of 2.31 times which implies that a large portion of operating profits are getting attributed to payment of interest to debtholders. This leaves lower earnings and cash flows for equity shareholders which is negative for returns.
Highly Cyclical Industry
The company operates an extremely cyclical business with unpredictable earnings and cash flows. This shall result in very high stock price volatility and returns which would negatively impact shareholder returns.
Poor Capital Allocation
The company has disproportionately high amount of assets locked up in working capital, cash and cash equivalents, loans and advances, etc to the extent of 77.82 % of total assets. This reflects poorly on the capital allocation strategy of the management which negatively impacts shareholder returns.
Poor Working Capital Cycle
The company has a very poor working capital cycle of 439 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.
Poor Corporate Governance
The general corporate governance standards of the company are poor which can negatively impact shareholder value and returns.

Valuation Analysis

Margin of safety
(09/05/2025)

Margin of Safety Index: High

0% People are bullish about Concord Drugs Ltd

0 % People are bearish about Concord Drugs Ltd

What is your opinion about this Stock?

Historical Data

Date	Open	High	Low	Close	Volume	Daily Change %